Go Deep
Cosmo Bio Company,Limited
Cosmo Bio Company,Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 22,452 | 19.2 | 0.72 | 0.00 | 743.39 |
Cosmo Bio Company,Limited Quarterly Results
| Line Item | Mar 2026 | Mar 2025 |
|---|---|---|
| EPS | 39.2 | 37.2 |
Cosmo Bio Company,Limited Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 10,766,000,000.0 | 10,037,000,000.0 | 9,340,000,000.0 | 9,553,000,000.0 | — |
| Net Profit | 337,000,000.0 | 262,000,000.0 | 442,000,000.0 | 517,000,000.0 | — |
| EPS | 59.3 | — | 76.0 | 89.1 | 126.9 |
Cosmo Bio Company,Limited Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 12,662,000,000.0 | 11,723,000,000.0 | 10,872,000,000.0 | 10,313,000,000.0 | — |
| Total Liabilities | 2,707,000,000.0 | 2,170,000,000.0 | 1,847,000,000.0 | 1,696,000,000.0 | — |
| Total Equity | 9,373,000,000.0 | 8,966,000,000.0 | 8,444,000,000.0 | 8,052,000,000.0 | — |
Owes vs Owns
Cosmo Bio Company,Limited owed ¥0.19 for every ¥1 it owned in Jun 2026, up from ¥0.16 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.19× | 0.21× | 0.19× | 0.17× | 0.16× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Cosmo Bio Company,Limited Assets & Liabilities Breakdown (JPY millions)
What it owns — Dec 2025
Cash & short-term investments 23.3%Receivables 24.4%Inventory 8.7%Fixed assets (tangible) 7.8%Intangible assets 1.3%Other assets 34.5%
How it's funded — Dec 2025
Payables 6.4%Other liabilities 14.9%Shareholders' equity 78.6%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 2,946.0 | 2,693.0 | 3,025.0 | 3,036.0 |
| Receivables | 3,085.0 | 3,002.0 | 2,851.0 | 2,799.0 |
| Inventory | 1,100.0 | 1,065.0 | 1,038.0 | 1,134.0 |
| Fixed assets (tangible) | 983.0 | 798.0 | 669.0 | 675.0 |
| Intangible assets | 167.0 | 162.0 | 155.0 | 171.0 |
| Long-term investments | 10.0 | 10.0 | 10.0 | 10.0 |
| Other assets | 4,371.0 | 3,993.0 | 3,124.0 | 2,488.0 |
| Liabilities & equity | ||||
| Short-term debt | 20.0 | 20.0 | 20.0 | 20.0 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Payables | 806.0 | 747.0 | 639.0 | 573.0 |
| Other liabilities | 1,881.0 | 1,403.0 | 1,188.0 | 1,103.0 |
| Shareholders' equity | 9,955.0 | 9,553.0 | 9,025.0 | 8,617.0 |
| Net tangible assets | 9,206.0 | 8,804.0 | 8,289.0 | 7,881.0 |
Cosmo Bio Company,Limited Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 595,000,000.0 | 241,000,000.0 | 736,000,000.0 | 284,000,000.0 | — |
| Investing Activities | 43,000,000.0 | -217,000,000.0 | -758,000,000.0 | -291,000,000.0 | — |
| Financing Activities | -283,000,000.0 | -479,000,000.0 | -201,000,000.0 | -236,000,000.0 | — |